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0014-5793  2012 Federation of European BiochemicChronic lymphocytic leukemia (CLL), the most common adult leukemia in the Western world, is
characterized by the progressive accumulation of small mature CD5+B lymphocytes in the peripheral
blood, lymphoid organs, and bone marrow (BM). The main feature of the disease is decreased apop-
tosis, resulting in the pathologic accumulation of these malignant cells. Appropriate cellular
responses to changes in oxygen tension during normal development or pathological processes, such
as cardiovascular disease and cancer, are ultimately regulated by the transcription factor, hypoxia-
inducible factor (HIF). Unlike their normal counterparts, CLL cells express HIF-1a even under nor-
moxia. In addition, overexpression of HIF-1a has been observed in leukemic cells in BM specimens
from CLL patients. The HIF transcription factor has been implicated in controlling the expression of a
wide variety of genes implicated in apoptosis, angiogenesis, invasion, and metastasis. This review
describes pathways regulating CLL survival with a focus on HIF-1a and its target genes, MIF and Mid-
kine (MK), and the potential cross-talk between these factors.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. CLL
Chronic lymphocytic leukemia (CLL), the most common Wes-
tern adult leukemia, is characterized by the progressive accumula-
tion of small mature CD5+ B lymphocytes in the peripheral blood,
lymphoid organs, and bone marrow (BM). The clinical course is
highly heterogeneous between different CLL patients. Advanced
clinical staging and high-risk molecular prognostic features
(high-risk cytogenetic abnormalities, unmutated IgVH, ZAP70 and
CD38 positivity) are associated with more rapid disease progres-
sion and shorter survival [1]. The main feature of CLL is decreased
apoptosis of the malignant cells, resulting in the pathologic accu-
mulation of these cells [2], although other processes such as cell
proliferation and clonal evolution are also involved [3].
CLL cells originate in peripheral lymphoid organs, but have a
propensity to invade the BM, which generally provides the reser-
voir of cells causing relapse. It was shown that the malignant CLL
cells have a predilection for the BM microenvironment, which ap-
pears to strongly support their extended survival [4]. Several stud-
ies demonstrated that CLL cells are protected by co-culture with
deﬁned accessory cells, such as mesenchymal marrow stromal
cells [5,6], follicular dendritic cells (FDC) [7] or monocyte-derived
nurse-like cells [8], which support CLL cell survival and the expres-
sion of anti-apoptotic proteins.achar).
al Societies. Published by ElsevierThe complex processes involved in proliferation and survival of
CLL cells have been discussed at length in a review by Calligaris-
Capio [3]. This review will focus on the role of the hypoxia-induc-
ible factor (HIF), and its potential ability to regulate CLL survival by
upregulating the expression of the cytokines Macrophage Migra-
tion Inhibitory Factor (MIF), and midkine (MK) (Fig. 1).
2. HIF-1
Cellular responses to changes in oxygen tension during normal
development or pathological processes, such as cardiovascular dis-
ease and cancer, are ultimately regulated by the transcription fac-
tor, hypoxia-inducible factor (HIF) [9]. Rapid growth of tumor cells
usually creates a hypoxic environment, which induces cell-adapta-
tion responses, such as HIF–dependent survival pathways and
angiogenesis. HIF transcription factors have been implicated in
controlling the expression of a wide variety of genes involved in
apoptosis, angiogenesis, invasion, and metastasis [9]. HIFs are basic
helix-loop-helix–PER–ARNT–SIM (bHLH–PAS) proteins that form
heterodimeric complexes comprised of an O2-labile a-subunit
(HIF-1a, HIF-2a or HIF-3a) and a stable b-subunit (HIF-1b; also
known as ARNT). Together, these subunits bind hypoxia-respon-
sive elements (HREs) [10]. Although HIF-1b is constitutively ex-
pressed, HIF-1a is rapidly induced by hypoxia. Hypoxic HIF
activity is controlled primarily through post-translational modiﬁ-
cation and stabilization of HIF-1a and HIF-2a subunits. HIFa sub-
units are modiﬁed by HIF-speciﬁc prolyl-hydroxylases (PHDs) inB.V. Open access under CC BY-NC-ND license.
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tion that is mediated in part by the von Hippel–Lindau (VHL) tu-
mour suppressor protein [10]. Another mechanism of inhibiting
HIF-1a function is mediated by ‘factor inhibiting HIF’ (FIH), which
prevents the transcriptional activation of HIF-1a by blocking the
interaction between the coactivators p300 and CREB binding pro-
tein [11]. During hypoxia, HIF-1b binds HIF-1a, preventing prote-
asomal degradation, and the complex is transported to the
nucleus, where it binds HIF response elements (HREs). The binding
of HIF-1a/HIF-1b to HREs assists in the recruitment of coactivator
molecules that form transcription initiation complexes, enhancing
the expression of target genes that mediate cellular and physio-
logic responses to hypoxia [12].
2.1. HIF-1 in CLL
Multiple xenograft tumour models support the hypothesis that
HIF-1a and HIF-2a promote tumor progression by regulating
expression of their target genes [10]. CLL cells constitutively ex-
press HIF-1a under normoxia [13]. Not only is HIF-1a overexpres-
sed and translocated in the nuclei of CLL B cells, but it is able to
form a complex with the transcriptional coactivator, p300, which
likely functions as a transcription factor [14]. The mechanism
inducing the high-resting level of HIF-1a in CLL cells appears to
be in part related to the ability of the HIF-1a to escape pVHL-med-
iated degradation. pVHL levels in CLL cells were found to be mark-
edly reduced in CLL cells compared with normal B cells [13]. The
microRNA, miR-92-1, known to be elevated in CLL B cells [15], is
able to target the VHL transcript and repress translation [13].
CLL cells accumulate in the BM during disease progression. The
endosteum at the murine bone–BM interface is hypoxic [16]. Data
in a rat model demonstrate that leukemic cells inﬁltrating bone
marrow are markedly hypoxic compared to cells in bone marrow
of healthy rats [17]. Similarly, overexpression of the oxygen-regu-
lated component of HIF-1, HIF-1a, has also been observed in leuke-
mic cells in BM specimens from CLL patients [18].
One of the best known effects of hypoxia and HIF-1a is upreg-
ulation of the vascular endothelial growth factor (VEGF) and stim-
ulation of angiogenesis. HIF-1a is a known transcription factor for
VEGF [19,20]. HIF-1a is able to form an active complex with the
transcriptional coactivator p300 and phosphorylated-STAT3 at
the VEGF promoter, and to recruit RNA polymerase II [13], which
might explain the spontaneous VEGF secretion by these leukemic
cells under normoxia. These high VEGF levels elevate the tissue
neovascularization in the marrow [21] and lymph nodes [22] of pa-
tients with CLL. Formation of new vessels through angiogenesis
represents an adaptive response to hypoxia and involves endothe-
lial cell proliferation, a process stimulated by hypoxia-inducible
growth factors, such as VEGF. The microvasculature is an active
component of the BM microenvironment and is responsible for
supplying appropriate oxygen and nutrients. As an essential regu-
lator of physiologic and pathologic angiogenesis, VEGF plays a vital
role in the growth and metastases of solid and hematologic malig-
nancies [23,24]. VEGF secreted by leukemic cells activates recep-
tors on both leukemic and endothelial cells, and stimulates their
proliferation. VEGF was found to inhibit apoptosis in leukemic cells
[25]. The ability of VEGF to alter CLL resistance to apoptosis is
linked to the expression of the VEGF receptors VEGF-R1, -R2, and
neuropilin receptor-1, found on CLL cells [26,27].
The role of HIF-1a in regulation of CLL survival was attributed
mainly to its ability to induce VEGF expression. Nevertheless, it
was previously shown that HIF-1a also induces the expression of
the cytokinesMIF [28], andmidkine (MK) [29],whichhave an essen-
tial role in CLL survival (see below and Fig. 1). It is possible that the
regulation by HIF-1a of MIF andmidkine expression can serve as an
additional level of regulation of the survival of these cells.3. MIF
The macrophage migration inhibitory factor (MIF) accounts for
one of the ﬁrst cytokine activities described [30]. Extensive studies
have revealed the central role of MIF in innate and adaptive immu-
nity. MIF promotes monocyte/macrophage activation and is re-
quired for the optimal expression of TNF-a, IL-1, and PGE2 [31].
The role of MIF in adaptive immunity is less fully characterized,
but antibody-based neutralization of MIF inhibits delayed-type
hypersensitivity, T cell priming, and antibody production in vivo
[31]. It was previously shown that MIF recognizes a cell surface
receptor, the CD74 extracellular domain, resulting in the initiation
of a signaling pathway [32].3.1. HIF-1 and MIF
The functional relationship between HIF-1 and MIF has been
investigated, indicating the HIF-dependent, as well as the HIF-
independent induction of MIF [33,34], and an indirect protein
interaction between HIF and MIF [28,35]. T helper cells are capable
of inducing HIF-1a and HIF-1 target genes under hypoxia. The
induction of MIF under hypoxia is a manifestation of HIF-1 activity.
MIF, in turn, is a key regulator of hypoxia-induced HIF-1a protein
expression, a process mediated by the MIF receptor, CD74, thereby
forming an autocrine positive-feedback loop [36].
In transformed cells, MIF was shown to modulate and to be
modulated by HIF-1 [28]. In addition, MIF overexpression in hu-
man breast cancer cell lines was found to promote hypoxia-in-
duced HIF-1a stabilization [35]. The MIF receptor CD74 was
shown to mediate HIF-1 activation by MIF [35]. Moreover, hypox-
ia-induced VEGF expression is signiﬁcantly reduced in MIF-deﬁ-
cient cells and increased in MIF over-expressing cells, consistent
with its contribution to HIF-1a stabilization [28,35].
3.2. Regulation of CLL survival by MIF and its receptor CD74
CD74 is a non-polymorphic type II integral membrane protein
that is expressed on antigen presenting cells. The CD74 chain
was initially thought to function mainly as a chaperone of MHC
class II molecules [37]. A small proportion of CD74 is modiﬁed by
the addition of chondroitin sulfate (CD74-CS), and this form of
CD74 is expressed on the cell surface. CD74 was reported to be a
high-afﬁnity receptor for MIF [32].
MIF and CD74 are associated with tumor progression. MIF was
shown to be overexpressed in solid tumors [38], and it is fre-
quently overexpressed in primary breast cancer tissues, where it
plays a role in tumor-stroma interactions of primary breast cancers
[39] and CLL [40]. MIF is also associated with tumor growth and tu-
mor-associated angiogenesis in a murine colon cancer cell line
[41]. In addition, anti-MIF Ig therapy was shown to suppress tumor
growth [42]. CD74 overexpression was observed in various cancers
[43–48] including CLL [49,50]. CD74 expression in solid tumors has
been suggested to serve as a prognostic factor, with higher relative
expression of CD74 behaving as a marker of disease progression
[51].
Similarly to their role in peripheral B cells [52–56], CD74 andMIF
were shown to play a pivotal role in the regulation of CLL cell sur-
vival [40]. CLL cells markedly upregulate both expression of their
cell surface CD74, and their MIF production. Stimulation of CD74
with the MIF ligand (or with an agonistic antibody) initiates a sig-
naling cascade leading to IL-8 transcription and secretion in all
CLL cells, regardless of the clinical status of the patients [40]. Se-
creted IL-8 induces the transcription and translation of the anti-
apoptotic protein, Bcl-2, and thereby regulates an anti-apoptotic







Fig. 1. Scheme showing potential interactions between the HIF-1a, MIF and MK survival cascades in CLL cells.
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regulation of Bcl-2 expression, and augmentation of apoptosis [40].
The BM stroma plays an essential role in B- lymphopoiesis, and
can provide survival niches for both normal and leukemic mature B
cells. The adhesion of CLL cells to BM stromal cells or to the BM
vasculature has been shown to rescue these lymphocytes from
apoptosis and to extend their life span [4,57]. The increased accu-
mulation of CLL cells in the BM during disease progression suggests
a change in the migratory and homing pattern of these cells. Ad-
vanced stage CLL cells express higher levels of the VLA-4 integrin
compared to early stage cells [58–61]. MIF and CD74 were demon-
strated to play a signiﬁcant role in the regulation of VLA-4 expres-
sion, and therefore, to affect homing of CLL cells to this
compartment [61]. MIF is secreted from all cell types; therefore
CLL cells are stimulated by this chemokine in all compartments
[31]. MIF stimulation elevates VLA-4 cell surface expression levels
during advanced stage disease [61]. Homing to the BM requires
threshold levels of VLA-4 expression that enable retention and sur-
vival of CLL in the BM, an environment that is enriched with the
VLA-4 ligands, VCAM-1 and ﬁbronectin, and further supports their
retention and survival. It is possible that CLL exposure to systemic
MIF redirects circulating CLL cells back to the BM, where they may
encounter additional MIF, and further elevate their VLA-4 expres-
sion and retention on stromal VLA-4 ligands.
4. Midkine (MK)
Midkine (MK) is a member of the heparin-binding growth and
differentiation factor family. It is the founding member of this fam-
ily, which is composed of only two members in humans. The other
member is Pleiotrophin, also called HB-GAM [62]. MK is a basic
cysteine-rich polypeptide with a molecular mass of 13 kDa
[63,64]. It promotes growth, survival, migration and gene expres-
sion of various target cells. It is involved in reproduction and re-
pair, and also plays pathological roles in many diseases [62].Several cell-surface receptors were discovered to bind to MK,
including members of the syndecan family, namely syndecan-1, -
3, and -4 [65], a protein-tyrosine phosphatase f (PTPf) [66], a trans-
membrane protein low density lipoprotein (LDL) receptor-related
protein (LRP) [67], the anaplastic lymphoma kinase (ALK) [68],
and the integrins a4b1 and a6b1 [69]. Moreover, MK can also bind
to nucleolin, a nuclear protein that is located at the cell surface and
functions as a shuttle to the nucleus [70]. This nuclear transloca-
tion is necessary for the anti-apoptotic activity of MK, thereby indi-
cating that MK may act not only through receptor-induced
signaling, but also directly within cells [71]. After MK stimulation,
activation of PI3 kinase/Akt and MAP kinase occurs, followed by
caspase suppression [72].
4.1. HIF-1 and MK
HIF-1a was shown to enhance the transcription of MK, acting
on HIF-1a regulatory elements located in the MK gene promoter
[29]. Site directed mutagenesis of the 3’ HIF response element in
the MK promoter blocks the stimulatory effects of HIF-1a. In addi-
tion, MK expression was shown to be induced by hypoxia. Expres-
sion of MK in the respiratory epithelium is regulated by HIF-1a
[29].
4.2. MK as a regulator of CLL survival
MK is signiﬁcantly up regulated in various malignant tumors
and plays crucial roles in carcinogenesis. Its expression has been
shown to be strongly correlated with poor prognosis in patients
with neuroblastomas, astrocytomas, pancreatic head carcinomas,
or gastrointestinal stromal tumors (reviewed in:[62,73]). In accor-
dance with its high expression in various malignant tumors, MK
exerts cancer-related activities in the process of carcinogenesis,
including transformation, ﬁbrinolysis, cell migration, enhancement
of cell survival and angiogenesis, and anti-apoptotic effects [74].
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individuals, regardless of the disease stage [75]. MK was shown to
be a target molecule of the MIF induced peripheral B cell survival
cascade [75]. MK and its receptor RPTPf play a major role in sur-
vival of CLL cells. MK suppresses CLL apoptosis by elevating the
expression of Bcl-2, and inhibiting caspase 3 and 7 activity. More-
over, incubation of CLL cells with a blocking antibody that recog-
nizes the extracellular domain of RPTPf results in induction of
cell death and inhibition of the MIF/CD74-induced survival cas-
cade, thereby demonstrating the major role of the MK/RPTPf path-
ways in the MIF/CD74 survival cascade in CLL [75].5. Concluding remarks
Despite major progress over the last few years in the under-
standing of the biology and pathophysiology of CLL, as well as
the development of better treatment modalities, this disease re-
mains incurable in most patients, and even control of the disease
requires aggressive treatment with signiﬁcant side effects. A better
understanding of the cellular events involved in the pathogenesis
and progression of the disease should lead to more speciﬁcally tar-
geted and less toxic therapies, with earlier treatment of high risk
patients, possibly resulting in cure. The hallmark of CLL is mainly
decreased apoptosis, resulting in accumulation of these malignant
cells. Blockade of HIF-1a, MIF and MK can be suggested as novel
therapeutic strategies aimed at inhibiting the homing and survival
of CLL cells.
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